Cheap arthritis drug may keep bypass grafts working longer
NCT ID NCT07569328
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking a low dose of colchicine (0.5 mg) every day for two years after coronary artery bypass grafting (CABG) can prevent the new blood vessel grafts from failing. About 622 adults who just had bypass surgery will be randomly assigned to get either colchicine or a placebo pill, on top of standard heart medications. The main goal is to see if colchicine reduces the rate of graft blockage or narrowing, as measured by a CT scan at 24 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Colchicine (0.5 mg pill daily)
What this could lead to
If it works, this could provide a simple, low-cost way to keep bypass grafts open longer, reducing the need for repeat procedures.
What could go wrong
This is a single-center trial that hasn't started recruiting yet. Colchicine can cause digestive issues or muscle pain, and the benefit over standard care is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CABG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100029, China